ANIK
Anika Therapeutics, Inc.
Price Chart
Latest Quote
$14.48
-0.31 (-2.10%)
Current Price
| Previous Close | $14.79 |
| Open | $14.75 |
| Day High | $14.89 |
| Day Low | $14.37 |
| Volume | 42,209 |
Stock Information
| Shares Outstanding | 13.31M |
| Total Debt | $25.74M |
| Cash Equivalents | $41.02M |
| Revenue | $116.26M |
| Net Income | $-11.08M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $192.67M |
| EPS (TTM) | $-0.79 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $177.38M |
| Sales | $116.26M |
| Income | $-11.08M |
| Book/sh | $10.03 |
| Cash/sh | $3.08 |
| Employees | 235 |
Financial Ratios
| Quick Ratio | 3.19 |
| Current Ratio | 4.46 |
| Debt/Eq | 19.22 |
Returns & Margins
| ROA | -4.14% |
| ROE | -7.85% |
| Gross Margin | 58.59% |
| Operating Margin | -18.53% |
| Profit Margin | -9.52% |
Ownership
| Insider Ownership | 5.97% |
| Institutional Ownership | 94.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 31.48 |
| PEG | 3.53 |
| P/S | 1.66 |
| P/B | 1.44 |
Analyst Data
| Recommendation | none |
| Target Price | $17.50 |
Technical Indicators
| SMA20 | $14.78 |
| SMA50 | $14.85 |
| SMA200 | $11.33 |
| RSI | 40.93 |
| ATR | 0.5314 |
| Shares Float | 11.28M |
| Short Float | 5.59% |
| Short Ratio | 4.86 |
| Volatility | 0.23 |
| Rel Volume | 0.60 |
Performance History
| Week | -0.34% |
| Month | -4.23% |
| Quarter | +2.55% |
| 6 Months | +52.90% |
| YTD | +54.87% |
| Year | +24.29% |
| 3 Years | -46.55% |
| 5 Years | -68.96% |
| 10 Years | -69.80% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $14.48 | 42,700 |
| 2026-06-04 | $14.79 | 59,700 |
| 2026-06-03 | $14.41 | 49,300 |
| 2026-06-02 | $14.38 | 57,600 |
| 2026-06-01 | $14.63 | 80,800 |
| 2026-05-29 | $14.53 | 99,700 |
| 2026-05-28 | $14.90 | 113,700 |
| 2026-05-27 | $14.81 | 37,600 |
| 2026-05-26 | $14.89 | 56,100 |
| 2026-05-22 | $14.88 | 50,800 |
| 2026-05-21 | $15.02 | 56,500 |
| 2026-05-20 | $15.14 | 59,200 |
| 2026-05-19 | $14.82 | 99,900 |
| 2026-05-18 | $14.95 | 72,800 |
| 2026-05-15 | $14.91 | 71,200 |
| 2026-05-14 | $15.34 | 123,800 |
| 2026-05-13 | $14.80 | 46,000 |
| 2026-05-12 | $14.68 | 50,100 |
| 2026-05-11 | $14.54 | 74,000 |
| 2026-05-08 | $14.77 | 110,700 |
| 2026-05-07 | $15.14 | 83,700 |
| 2026-05-06 | $15.12 | 109,800 |
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
đ° Latest News
President of Anika Therapeutics Picks Up 51% More Stock
Simply Wall St. âĸ 2026-05-03T13:36:28Z
Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-04-29T16:50:22Z
Anika Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-29T14:20:26Z
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
Exec Edge âĸ 2026-04-07T19:35:47Z
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
MarketBeat âĸ 2026-03-03T08:29:08Z
Anika Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-02-27T13:30:00Z
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: Strong International Growth and ...
GuruFocus.com âĸ 2026-02-26T21:09:13ZAnika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Zacks âĸ 2026-02-26T17:15:03Z
Anika Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-02-26T15:59:26Z
Anika: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-02-26T12:35:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $49,012,000 | $43,909,000 | $38,260,000 | $40,607,000 |
| Cost Of Revenue | $49,012,000 | $43,909,000 | $38,260,000 | $40,607,000 |
| Total Revenue | $112,819,000 | $119,907,000 | $120,792,000 | $113,827,000 |
| Operating Revenue | $112,819,000 | $119,907,000 | $120,792,000 | $113,827,000 |
| Expenses | ||||
| Total Expenses | $123,870,000 | $125,008,000 | $119,948,000 | $110,157,000 |
| Net Non Operating Interest Income Expense | $1,744,000 | $2,337,000 | $2,312,000 | $654,000 |
| Total Other Finance Cost | $-1,744,000 | $-2,337,000 | $-2,312,000 | $-654,000 |
| Operating Expense | $74,858,000 | $81,099,000 | $81,688,000 | $69,550,000 |
| Other Income Expense | - | - | $-62,190,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,979,000 | $-8,828,000 | $-3,439,000 | $2,200,000 |
| Net Interest Income | $1,744,000 | $2,337,000 | $2,312,000 | $654,000 |
| Normalized Income | $-9,979,000 | $-8,828,000 | $-3,439,000 | $2,200,000 |
| Net Income From Continuing And Discontinued Operation | $-10,880,000 | $-56,385,000 | $-82,667,000 | $-14,859,000 |
| Total Operating Income As Reported | $-11,051,000 | $-5,101,000 | $844,000 | $3,670,000 |
| Net Income Common Stockholders | $-10,880,000 | $-56,385,000 | $-82,667,000 | $-14,859,000 |
| Net Income | $-10,880,000 | $-56,385,000 | $-82,667,000 | $-14,859,000 |
| Net Income Including Noncontrolling Interests | $-10,880,000 | $-56,385,000 | $-82,667,000 | $-14,859,000 |
| Net Income Discontinuous Operations | $-901,000 | $-47,557,000 | $-79,228,000 | $-17,059,000 |
| Net Income Continuous Operations | $-9,979,000 | $-8,828,000 | $-3,439,000 | $2,200,000 |
| Pretax Income | $-9,307,000 | $-2,764,000 | $3,156,000 | $4,324,000 |
| Operating Income | $-11,051,000 | $-5,101,000 | $844,000 | $3,670,000 |
| Gross Profit | $63,807,000 | $75,998,000 | $82,532,000 | $73,220,000 |
| Special Income Charges | - | - | $-62,190,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.76 | $-3.83 | $-5.64 | $-1.02 |
| Basic EPS | $-0.76 | $-3.83 | $-5.64 | $-1.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,322,000 | $3,020,000 | $15,061,000 | $18,157,000 |
| Reconciled Depreciation | $5,729,000 | $8,121,000 | $14,217,000 | $14,487,000 |
| EBITDA (Bullshit earnings) | $-5,322,000 | $3,020,000 | $15,061,000 | $18,157,000 |
| EBIT | $-11,051,000 | $-5,101,000 | $844,000 | $3,670,000 |
| Diluted Average Shares | $14,339,000 | $14,721,932 | $14,656,000 | $14,561,000 |
| Basic Average Shares | $14,339,000 | $14,721,932 | $14,656,000 | $14,561,000 |
| Diluted NI Availto Com Stockholders | $-10,880,000 | $-56,385,000 | $-82,667,000 | $-14,859,000 |
| Tax Provision | $672,000 | $6,064,000 | $6,595,000 | $2,124,000 |
| Research And Development | $25,770,000 | $25,544,000 | $21,763,000 | $18,321,000 |
| Selling General And Administration | $49,088,000 | $55,555,000 | $59,925,000 | $51,229,000 |
| Total Unusual Items | - | - | $-62,190,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | - | $-62,190,000 | $0 |
| Impairment Of Capital Assets | - | - | $62,190,000 | $0 |
| Restructuring And Mergern Acquisition | - | - | $0 | $0 |
Fetched: 2026-06-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $133,761,000 | $144,374,000 | $202,118,000 | $203,625,000 |
| Total Assets | $190,270,000 | $202,740,000 | $270,632,000 | $349,128,000 |
| Total Non Current Assets | $86,912,000 | $89,088,000 | $107,323,000 | $179,581,000 |
| Other Non Current Assets | $4,034,000 | $7,682,000 | $30,688,000 | $17,219,000 |
| Non Current Deferred Assets | $1,275,000 | $1,177,000 | $1,489,000 | $1,449,000 |
| Non Current Deferred Taxes Assets | $1,275,000 | $1,177,000 | $1,489,000 | $1,449,000 |
| Non Current Note Receivables | $5,636,000 | $5,935,000 | $0 | - |
| Goodwill And Other Intangible Assets | $9,704,000 | $9,615,000 | $10,147,000 | $81,938,000 |
| Other Intangible Assets | $1,650,000 | $2,490,000 | $2,576,000 | $74,599,000 |
| Current Assets | $103,358,000 | $113,652,000 | $163,309,000 | $169,547,000 |
| Other Current Assets | $3,400,000 | $5,494,000 | $7,476,000 | $8,828,000 |
| Assets Held For Sale Current | $0 | $5,126,000 | $36,305,000 | - |
| Inventory | $18,787,000 | $23,809,000 | $24,428,000 | $39,765,000 |
| Receivables | $23,690,000 | $23,594,000 | $26,360,000 | $34,627,000 |
| Accounts Receivable | $23,690,000 | $23,594,000 | $26,360,000 | $34,627,000 |
| Allowance For Doubtful Accounts Receivable | $-1,127,000 | $-730,000 | $-666,000 | $-1,608,000 |
| Gross Accounts Receivable | $24,817,000 | $24,324,000 | $27,026,000 | $36,235,000 |
| Cash Cash Equivalents And Short Term Investments | $57,481,000 | $55,629,000 | $68,740,000 | $86,327,000 |
| Cash And Cash Equivalents | $57,481,000 | $55,629,000 | $68,740,000 | $86,327,000 |
| Prepaid Assets | - | - | - | $8,828,000 |
| Debt | ||||
| Total Debt | $26,248,000 | $25,932,000 | $27,742,000 | $30,890,000 |
| Long Term Debt And Capital Lease Obligation | $24,196,000 | $24,014,000 | $25,915,000 | $28,817,000 |
| Current Debt And Capital Lease Obligation | $2,052,000 | $1,918,000 | $1,827,000 | $2,073,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $46,805,000 | $48,751,000 | $58,367,000 | $63,565,000 |
| Total Non Current Liabilities Net Minority Interest | $24,897,000 | $25,445,000 | $27,308,000 | $35,651,000 |
| Other Non Current Liabilities | $701,000 | $772,000 | $404,000 | $398,000 |
| Liabilities Heldfor Sale Non Current | $0 | $659,000 | $989,000 | - |
| Current Liabilities | $21,908,000 | $23,306,000 | $31,059,000 | $27,914,000 |
| Payables And Accrued Expenses | $8,750,000 | $9,225,000 | $10,506,000 | $14,538,000 |
| Payables | $6,041,000 | $5,680,000 | $7,434,000 | $9,884,000 |
| Total Tax Payable | $0 | $63,000 | $1,240,000 | $810,000 |
| Income Tax Payable | $0 | $63,000 | $1,240,000 | $810,000 |
| Accounts Payable | $6,041,000 | $5,617,000 | $6,194,000 | $9,074,000 |
| Other Current Liabilities | - | $4,122,000 | $10,799,000 | - |
| Non Current Deferred Liabilities | - | - | $0 | $6,436,000 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $6,436,000 |
| Equity | ||||
| Common Stock Equity | $143,465,000 | $153,989,000 | $212,265,000 | $285,563,000 |
| Total Equity Gross Minority Interest | $143,465,000 | $153,989,000 | $212,265,000 | $285,563,000 |
| Stockholders Equity | $143,465,000 | $153,989,000 | $212,265,000 | $285,563,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,959,000 | $-6,783,000 | $-5,943,000 | $-6,443,000 |
| Other Equity Adjustments | $-4,959,000 | $-6,783,000 | $-5,943,000 | $-6,443,000 |
| Retained Earnings | $60,787,000 | $71,667,000 | $128,052,000 | $210,719,000 |
| Other | ||||
| Treasury Shares Number | $1,496,000 | $594,000 | $188,000 | - |
| Ordinary Shares Number | $13,889,000 | $14,416,000 | $14,660,000 | $14,625,000 |
| Share Issued | $15,385,000 | $15,010,000 | $14,848,000 | $14,625,000 |
| Tangible Book Value | $133,761,000 | $144,374,000 | $202,118,000 | $203,625,000 |
| Invested Capital | $143,465,000 | $153,989,000 | $212,265,000 | $285,563,000 |
| Working Capital | $81,450,000 | $90,346,000 | $132,250,000 | $141,633,000 |
| Capital Lease Obligations | $26,248,000 | $25,932,000 | $27,742,000 | $30,890,000 |
| Total Capitalization | $143,465,000 | $153,989,000 | $212,265,000 | $285,563,000 |
| Additional Paid In Capital | $87,498,000 | $88,961,000 | $90,009,000 | $81,141,000 |
| Capital Stock | $139,000 | $144,000 | $147,000 | $146,000 |
| Common Stock | $139,000 | $144,000 | $147,000 | $146,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $24,196,000 | $24,014,000 | $25,915,000 | $28,817,000 |
| Current Capital Lease Obligation | $2,052,000 | $1,918,000 | $1,827,000 | $2,073,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,106,000 | $8,041,000 | $7,927,000 | $11,303,000 |
| Current Accrued Expenses | $2,709,000 | $3,545,000 | $3,072,000 | $4,654,000 |
| Goodwill | $8,054,000 | $7,125,000 | $7,571,000 | $7,339,000 |
| Net PPE | $66,263,000 | $64,679,000 | $64,999,000 | $78,975,000 |
| Accumulated Depreciation | $-51,428,000 | $-46,284,000 | $-43,987,000 | $-46,183,000 |
| Gross PPE | $117,691,000 | $110,963,000 | $108,986,000 | $125,158,000 |
| Leases | $36,824,000 | $36,340,000 | $34,654,000 | $34,916,000 |
| Construction In Progress | $3,729,000 | $6,039,000 | $2,390,000 | $5,021,000 |
| Other Properties | $75,442,000 | $67,075,000 | $70,209,000 | $82,808,000 |
| Machinery Furniture Equipment | $1,696,000 | $1,509,000 | $1,733,000 | $2,413,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | - | - | - | $-16,724,000 |
| Finished Goods | - | - | - | $25,306,000 |
| Work In Process | - | - | - | $10,648,000 |
| Raw Materials | - | - | - | $20,535,000 |
Fetched: 2026-06-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $4,362,000 | $-2,931,000 | $-7,215,000 | $-3,077,000 |
| Operating Activities | ||||
| Operating Cash Flow | $11,188,000 | $5,403,000 | $-1,788,000 | $4,409,000 |
| Cash Flow From Continuing Operating Activities | $11,188,000 | $5,403,000 | $-1,788,000 | $4,409,000 |
| Operating Gains Losses | $-166,000 | $2,864,000 | $1,917,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-6,826,000 | $-8,334,000 | $-5,427,000 | $-7,486,000 |
| Investing Cash Flow | $-401,000 | $-8,334,000 | $-5,427,000 | $-7,486,000 |
| Cash Flow From Continuing Investing Activities | $-401,000 | $-8,334,000 | $-5,427,000 | $-7,486,000 |
| Net Other Investing Changes | $5,825,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-9,485,000 | $-10,914,000 | $-5,000,000 | $0 |
| Financing Cash Flow | $-10,551,000 | $-12,729,000 | $-6,324,000 | $-4,852,000 |
| Cash Flow From Continuing Financing Activities | $-10,551,000 | $-12,729,000 | $-6,324,000 | $-4,852,000 |
| Net Other Financing Charges | $-1,566,000 | $-2,599,000 | $-2,152,000 | $-5,249,000 |
| Net Common Stock Issuance | $-9,485,000 | $-10,914,000 | $-5,000,000 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $1,076,000 | $3,993,000 | $3,117,000 | $106,000 |
| End Cash Position | $57,481,000 | $57,159,000 | $72,867,000 | $86,327,000 |
| Beginning Cash Position | $57,159,000 | $72,867,000 | $86,327,000 | $94,386,000 |
| Effect Of Exchange Rate Changes | $86,000 | $-48,000 | $79,000 | $-130,000 |
| Changes In Cash | $236,000 | $-15,660,000 | $-13,539,000 | $-7,929,000 |
| Proceeds From Stock Option Exercised | $500,000 | $784,000 | $828,000 | $681,000 |
| Common Stock Payments | $-9,485,000 | $-10,914,000 | $-5,000,000 | $0 |
| Net Intangibles Purchase And Sale | $600,000 | $-600,000 | $0 | $0 |
| Sale Of Intangibles | $600,000 | $0 | $0 | - |
| Purchase Of Intangibles | $0 | $-600,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-6,826,000 | $-7,734,000 | $-5,427,000 | $-7,486,000 |
| Purchase Of PPE | $-6,826,000 | $-7,734,000 | $-5,427,000 | $-7,486,000 |
| Change In Working Capital | $-823,000 | $-13,092,000 | $-12,123,000 | $-11,821,000 |
| Change In Other Working Capital | $-134,000 | $665,000 | $530,000 | $1,437,000 |
| Change In Other Current Liabilities | $-1,996,000 | $-2,082,000 | $-2,149,000 | $-1,485,000 |
| Change In Payables And Accrued Expense | $-1,458,000 | $-6,175,000 | $1,637,000 | $1,522,000 |
| Change In Accrued Expense | $-1,500,000 | $-3,669,000 | $1,648,000 | $-443,000 |
| Change In Payable | $42,000 | $-2,506,000 | $-11,000 | $1,965,000 |
| Change In Account Payable | $42,000 | $-2,506,000 | $-11,000 | $1,965,000 |
| Change In Prepaid Assets | $2,327,000 | $558,000 | $560,000 | $-792,000 |
| Change In Inventory | $30,000 | $-9,424,000 | $-11,396,000 | $-6,873,000 |
| Change In Receivables | $408,000 | $3,366,000 | $-1,305,000 | $-5,630,000 |
| Changes In Account Receivables | $408,000 | $3,366,000 | $-1,305,000 | $-5,630,000 |
| Other Non Cash Items | $1,165,000 | $2,150,000 | $2,231,000 | $1,850,000 |
| Stock Based Compensation | $10,084,000 | $13,130,000 | $15,243,000 | $14,315,000 |
| Provisionand Write Offof Assets | $6,086,000 | $45,893,000 | $3,531,000 | $5,707,000 |
| Asset Impairment Charge | $0 | $2,462,000 | $62,190,000 | $0 |
| Deferred Tax | $-7,000 | $260,000 | $-6,327,000 | $-5,270,000 |
| Deferred Income Tax | $-7,000 | $260,000 | $-6,327,000 | $-5,270,000 |
| Depreciation Amortization Depletion | $5,729,000 | $8,121,000 | $14,217,000 | $14,487,000 |
| Depreciation And Amortization | $5,729,000 | $8,121,000 | $14,217,000 | $14,487,000 |
| Amortization Cash Flow | $357,000 | $1,237,000 | $7,783,000 | $7,783,000 |
| Amortization Of Intangibles | $357,000 | $1,237,000 | $7,783,000 | $7,783,000 |
| Depreciation | $5,372,000 | $6,884,000 | $6,434,000 | $6,704,000 |
| Gain Loss On Sale Of PPE | $-166,000 | $2,864,000 | $1,917,000 | $0 |
| Net Income From Continuing Operations | $-10,880,000 | $-56,385,000 | $-82,667,000 | $-14,859,000 |
| Repayment Of Debt | - | $0 | $0 | $-284,000 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $-284,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $-284,000 |
| Long Term Debt Payments | - | $0 | $0 | $-284,000 |
| Net Investment Purchase And Sale | - | - | $0 | $0 |
| Sale Of Investment | - | - | $0 | $0 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $0 |
Fetched: 2026-06-01